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Atrophy of skeletal muscle reduces both the quality and quantity of life of patients with cancer cachexia. Loss of muscle mass is
thought to arise from a reduction in protein synthesis combined with an enhanced rate of protein degradation, and few treatments
are available to counteract this process. Eicosapentaenoic acid (EPA) has been shown to attenuate the enhanced protein degradation,
but to have no effect on protein synthesis. This study examines the effect of EPA combined with a protein and amino-acid
supplementation on protein synthesis and degradation in gastrocnemius muscle of mice bearing the cachexia-inducing MAC16
tumour. Muscles from cachectic mice showed an 80% reduction in protein synthesis and about a 50-fold increase in protein
degradation compared with muscles from nontumour-bearing mice of the same age and weight. Treatment with EPA (1gkg
 1) daily
reduced protein degradation by 88%, but had no effect on protein synthesis. Combination of EPA with casein (5.35gkg
 1) also had
no effect on protein synthesis, but when combined with the amino acids leucine, arginine and methionine there was almost a doubling
of protein synthesis. The addition of carbohydrate (10.7gkg
 1) to stimulate insulin release had no additional effect. The combination
involving the amino acids produced almost a doubling of the ratio of protein synthesis to protein degradation in gastrocnemius muscle
over that of EPA alone. No treatment had a significant effect on tumour growth rate, but the inclusion of amino acids had a more
significant effect on weight loss induced by the MAC16 tumour than that of EPA alone. The results suggest that combination therapy
of cancer cachexia involving both inhibition of the enhanced protein degradation and stimulation of the reduced protein synthesis
may be more effective than either treatment alone.
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Atrophy of skeletal muscle in cancer cachexia results in weakness
(asthenia) and death. Muscle mass is controlled by the rate of
protein synthesis and the rate of protein degradation, which in
the adult are normally in balance, so that muscle mass remains
constant. In cachexia whole body protein turnover is increased
(Carmichael et al, 1980), while in skeletal muscle protein synthesis
is decreased (Lundholm et al, 1976), while protein degradation is
elevated (Lundholm et al, 1982). Attempts to increase protein
synthesis, for example, by elevation of substrate flux, in the
absence of inhibitors of protein degradation have not increased
lean body mass (Evans et al, 1985). Protein degradation in cancer
cachexia has been attributed predominantly to an increased
expression of the ubiquitin–proteasome proteolytic pathway
(Lecker et al, 1999). One of the few agents capable of attenua-
ting protein degradation in cachexia is the polyunsaturated fatty
acid, eicosapentaenoic acid (EPA), which downregulates the
increased gene expression of key regulatory components of the
ubiquitin–proteasome pathway in skeletal muscle (Whitehouse
et al, 2001). Although EPA attenuates the increased protein
degradation in cancer cachexia, it has no effect on the depression
of protein synthesis (Beck et al, 1991). Thus, EPA attenuates
the development of weight loss in cachectic patients with pan-
creatic cancer, but weight gain is minimal (Wigmore et al, 2000).
However, when patients were administered EPA together with
a high-protein high-energy supplement weight gain was seen
and this arose solely from an increase in lean body mass (Barber
et al, 1999).
This suggests a mechanism to counter muscle atrophy in cancer
cachexia by the inhibition of protein degradation, combined with a
stimulus for protein synthesis. Muscle protein synthesis has been
shown to be initiated by essential amino acids, particularly the
branched chain amino-acid (BCAA) leucine (Anthony et al, 2000).
Stimulation of protein synthesis requires an optimal plasma profile
of amino acids and occurs through a mechanism that involves the
stimulation of the eukaryotic initiation factor (eIF)-binding
protein 1. Arginine is a conditionally essential amino acid, which
has been shown to be deficient in tumour-bearing mice (Vissers
et al, 2002). Arginine may improve the delivery of amino acids to
muscle (Robertson et al, 1994), and thus may increase protein
synthesis. Methionine is another essential amino acid, which may
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sbe rate limiting in protein synthesis. It has recently been shown
(Tesseraud et al, 2003) that simultaneous addition of two amino
acids, leucine and methionine, are critical in controlling protein
translation. Methionine is not only a building block for proteins
but is also the primary amino acid needed to initiate protein
synthesis (Bradshaw et al, 1998). In addition, synthesis of acute
phase proteins, which has been correlated with the loss of body
mass in patients with lung and gastrointestinal cancers (McMillan
et al, 1998), alters requirements for amino acids, since these
proteins contain relatively high levels of sulphur-containing amino
acids (Reeds et al, 1997). Lower plasma levels of leucine and
methionine have been reported in the serum of weight-losing mice
bearing the MAC16 tumour (Beck and Tisdale, 1989).
The purpose of the present study was to investigate the effect of
protein (casein) and amino acids (leucine, arginine and methionine)
together with EPA on protein synthesis and degradation in
gastrocnemius muscle of mice bearing the MAC16 colon adeno-
carcinoma (Bibby et al, 1987). An additional group received carbo-
hydrate, to stimulate insulin release, which should facilitate the
uptake of amino acids into muscle and stimulate protein synthesis.
MATERIALS AND METHODS
Animals
Pure strain male NMRI mice were bred in our own colony and fed
economy rodent breeder diet (Special Diet Services, Essex, UK)
and water ad libitum. The diet contained 19.2% crude protein and
4.3% fat. Animals were implanted subcutaneously (s.c.) in the
flank with fragments of the MAC16 tumour by means of a trochar,
selecting from donor animals with established weight loss (Bibby
et al, 1987). All animal experiments followed a strict protocol,
approved by the British Home Office, and the ethical guidelines
that were followed meet the standards required by the UKCCR
guidelines (Workman et al, 1998). Weight loss was evident 10–12
days after transplantation and the animals were randomised into
groups of 12 when the weight loss was about 5%. Six animals were
used for protein synthesis and six for protein degradation. A
nontumour-bearing group formed an additional control. Cachectic
mice received olive oil as a control, EPA (1.0gkg
 1), EPA
(1.0gkg
 1 and casein protein 5.35gkg
 1), EPA (1.0gkg
 1, casein
5.35gkg
 1, leucine 25.5mg, arginine 12mg, methionine 5mg) and
EPA (1.0gkg
 1, casein 5.35gkg
 1, amino acids as above and
10.7gkg
 1 carbohydrate). The supplements were administered
twice daily in 50ml doses. All treatments were administered daily
peritoneally (p.o.) by gavage for a 4-day period and protein
synthesis and degradation were determined on the 4th day. The
concentrations of protein, amino acids and carbohydrate were
equivalent to those consumed by patients taking the recommended
dosage of Resource
s Support (Novartis Medical Nutrition).
Tumour volumes were measured daily by means of calipers, and
were recorded as a percentage of the starting tumour volume. Body
weight was measured daily and recorded as the change in body
weight from the start of the experiment. At the end of the
experiment, the animals were humanely killed and the gastro-
cnemius muscles were rapidly removed for further analysis.
Materials
L-[4
 3H]Phenylalanine (specific activity 30Cimmol
 1) was pur-
chased from Amersham Life Science Products, Amersham UK.
EPA as the synthetic triglyceride, Omegavie 90, contained 93.2%
EPA as the fatty acid, and was purchased from Polaris, France. The
carbohydrate was 10DE maltodextrin from Grain Processing
Corporation, USA. The protein was a casein hydrolysate with the
same amino-acid profile as casein and was purchased from New
Zealand Milk Products.
Protein synthesis and degradation in gastrocnemius
muscle
The method for the determination of protein synthesis and
degradation in gastrocnemius muscle has been described pre-
viously (Beck et al, 1991). Briefly, protein synthesis was measured
by the incorporation of L-[4
 3H]phenylalanine during a 2h period
in which isolated gastrocnemius muscles were incubated at 371Ci n
RPMI 1640 without phenol red and saturated with O2:CO 2 (19:1).
After incubation, muscles were rinsed in nonradioactive medium,
blotted and homogenised in 4ml 2% perchloric acid. The rate of
protein synthesis was calculated by dividing the amount of
protein-bound radioactivity by the amount of acid-soluble radio-
activity.
For protein degradation assays animals from the same group as
used to measure protein synthesis were administered i.p. with
0.4mML -[4
 3H]phenylalanine in phosphate-buffered saline
(100ml) 24h prior to the assay. Isolated gastrocnemius muscles
were extensively washed with 0.9% NaCl and RPMI 1640 medium
before measuring the release of radioactivity into RPMI 1640 over
a 2h period. The protein-bound radioactivity was determined by
homogenising in 2% perchloric acid as above and the rate of
protein degradation was calculated by dividing the amount of
[
3H]phenylalanine radioactivity released into the incubation
medium during the 2h incubation period by the specific activity
of protein-bound [
3H]phenylalanine.
Statistical analysis
Results are expressed as mean7s.e.m. Differences were deter-
mined by one-way analysis of variance (ANOVA) followed by
Tukey–Kramer multiple comparison test. P-values less than 0.05
were considered significant.
RESULTS
The effects of the various treatments on protein synthesis and
protein degradation in gastrocnemius muscle of cachectic mice
bearing the MAC16 tumour is shown in Figure 1. The concentra-
tion of EPA used was suboptimal in order to discern synergistic
interactions. Control animals showed high levels of protein
synthesis and little protein degradation, which was expected, since
they were growing steadily. There was a significant depression in
protein synthesis and a large increase in protein degradation in
muscles of cachectic mice bearing the MAC16 tumour, as reported
previously (Beck et al, 1991). EPA treatment significantly reduced
protein degradation, but had no effect on protein synthesis. There
was no significant effect of any of the other treatments on protein
degradation compared with that of EPA alone. There was a small,
but nonsignificant elevation in protein synthesis in animals
receiving casein in addition to EPA. However, when casein was
administered together with leucine, arginine and methionine, there
was a significant increase in protein synthesis above that seen in
cachectic mice or cachectic mice administered EPA. Interestingly,
this effect was not seen in the presence of carbohydrate. The ratio
of protein synthesis to degradation was improved by all
supplement treatments over that of EPA alone (Figure 2), although
it never reached the values observed in nontumour-bearing mice.
The effect of the various treatments on body weight loss is
shown in Figure 3. Both EPA and EPAþcasein reduced total body
weight loss, but this did not reach significance except at the 4-day
time point. However, the addition of both amino acids and amino
acidsþcarbohydrate to the EPAþcasein regime caused a
significant reduction in weight loss compared with nontreated
controls. None of the treatments had a significant effect on tumour
volume (Figure 4).
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Figure 1 Protein synthesis (&) and degradation ( ) in gastrocnemius
muscle of nontumour-bearing mice (normal), cachectic mice (cachectic),
cachectic mice treated with EPA (EPA), cachectic mice treated with EPAþ
casein (EPAþC), cachectic mice treated with EPAþcaseinþamino acids
(EPAþCþAA), cachectic mice treated with EPAþcaseinþamino
acidsþcarbohydrate (EPAþCþAAþCHO). The details of the treat-
ments are given in the Materials and methods section. The weight loss in
the various groups is shown in Figure 3. Differences from control are
indicated as a, Po0.01 and b, Po0.001, while differences from cachectic
are indicated as c, Po0.05 and d, Po0.001 and differences from EPA as f,
Po0.05. The number of animals used for both protein synthesis and
protein degradation n¼6.
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Figure 2 Ratio of protein synthesis to protein degradation in
gastrocnemius muscle of cachectic mice bearing the MAC16 tumour after
being subjected to the nutritional regimes detailed in Figure 1 for a 4-day
period.
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Figure 3 Effect of nutritional supplementation on body weight loss
in mice bearing the MAC16 tumour. All animals were weight losing at
the time of initiation of the experiment (day 1). Animals (n¼12)
were randomised to receive daily p.o. treatments of olive oil (X), EPA
(’), EPAþcasein (J), EPAþcaseinþamino acids (K) or EPAþ
caseinþamino acidsþcarbohydrate (&) at the concentrations indi-
cated in the Materials and methods section. Differences from animals
receiving olive oil alone are indicated as a, Po0.05, b, Po0.01 and c,
Po0.001.
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Figure 4 Effect of nutritional supplementation on tumour growth in
mice bearing the MAC16 tumour. Tumour size has been normalised to
100% at the start of the experiment. Animals (n¼12) were randomised to
receive daily p.o. treatments of olive oil (X), EPA (’), EPAþcasein (J),
EPAþcaseinþamino acids (K) or EPAþcaseinþamino acidsþcarbo-
hydrate (&) at the concentrations indicated in the Materials and methods
section. There was no significant difference between the groups.
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sDISCUSSION
The mechanism for the increased protein degradation in skeletal
muscle in cancer cachexia has been suggested as an increased
expression of the ubiquitin–proteasome proteolytic pathway
(Williams et al, 1999). Various cytokines, such as tumour necrosis
factor-a or interferon gamma (Llovera et al, 1998), have been
shown to increase transcripts of ubiquitin in skeletal muscle, but
the importance of these cytokines as mediators of the weight loss
in human cancer cachexia is controversial (Maltoni et al, 1997). In
cancer cachexia, a sulphated glycoprotein, proteolysis-inducing
factor (PIF) produced by cachexia inducing tumours (Todorov
et al, 1996) may be more important in skeletal muscle atrophy.
Proteolysis-inducing factor stimulates loss of the myofibrillar
protein myosin directly by increasing the expression of protea-
some subunits and the ubiquitin-conjugating enzyme (E214k)
(Gomes-Marcondes et al, 2002). The process is initiated by the
activation of PIF of an intracellular signalling cascade in muscle
involving the release of arachidonic acid from membrane
phospholipids and metabolism to 15-hydroxyeicosatetraenoic acid
(15-HETE) (Smith et al, 1999), and involving the activation of the
transcription factor nuclear factor-kB (NF-kB) (Whitehouse and
Tisdale, 2003). Eicosapentaenoic acid attenuates this process, both
by inhibiting the formation of 15-HETE (Smith et al, 1999) and by
stabilising the IkB/NF-kB cytosolic complex and nuclear accumu-
lation of NF-kB (Whitehouse and Tisdale, 2003), preventing the
increase in proteasome expression and degradation of myofibrillar
proteins. Proteasome-mediated proteolysis is independent of the
amount of protein consumed, so that simple nutritional supple-
mentation would not be expected to prevent muscle catabolism as
observed in mice bearing the MAC16 tumour. However, leucine
has been shown to inhibit the expression of genes of the
proteasome pathway in muscle of cachectic rats, but not in those
of rats after starvation (Busquets et al, 2002). Branched chain
amino acids also directly inhibit the proteasome ‘chymotrypsin-
like’ enzyme activity, the predominant proteolytic activity of the b-
subunits of the proteasome in skeletal muscle, but not in the liver
(Hamel et al, 2003). Despite this in the present study, there was no
evidence for attenuation of protein degradation by leucine/amino-
acid mixture below that induced by EPA alone in gastrocnemius
muscle of cachectic mice bearing the MAC16 tumour.
In addition to the effect on protein degradation PIF also inhibits
protein synthesis in muscle, but the mechanism by which this
occurs is not known, although it is attenuated by insulin at
physiological concentrations and below, but not by EPA (Smith
et al, 1999). The action of insulin suggests that PIF may inhibit
translation, for example, by dephosphorylation of translation
factors or the S6 ribosomal protein. Branched chain amino-acid,
and leucine in particular, enhance muscle protein synthesis
through the activation of the mRNA-binding step in translation
initiation in skeletal muscle, but not in the liver (Yoshizawa, 2004).
The action of leucine is mediated by the activation of the
ribosomal protein S6 kinase and by phosphorylation of initiation
factors, suggesting that it may, like insulin, overcome the PIF-
induced inhibition of protein synthesis. This study shows that
while casein alone did not significantly stimulate protein synthesis
in gastrocnemius muscle of cachectic mice, there was a significant
increase in protein synthesis with the addition of the leucine/
arginine/methionine mix. This was not further enhanced by the
carbohydrate mix, although leucine and arginine have been
previously shown to stimulate insulin secretion (Malaisse, 1984),
and insulin plays a permissive role in leucine-induced protein
synthesis (Yoshizawa, 2004). Thus treatment of cancer patients
with a combination of EPA, protein and amino acids, particularly
leucine, would be expected to attenuate protein degradation and
stimulate protein synthesis in skeletal muscle, which should lead to
improvements both in the quality of life and survival, and this
combination is currently under clinical evaluation.
ACKNOWLEDGEMENTS
This work has been supported by Novartis Medical Nutrition,
Switzerland. We thank Mr M Wynter for performing the animal
experiments.
REFERENCES
Anthony JC, Anthony TG, Kimball SR, Vary TC, Jefferson IS (2000) Orally
administered leucine stimulates protein synthesis in skeletal muscle of
postabsorptive rats in association with increased eIF4F formation. J Nutr
130: 139–145
Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH (1999) The effect of
an oral nutritional supplement enriched with fish oil on weight-loss in
patients with pancreatic cancer. Br J Cancer 81: 80–86
Beck SA, Smith KL, Tisdale MJ (1991) Anticachectic and antitumor effect of
eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:
6089–6093
Beck SA, Tisdale MJ (1989) Nitrogen excretion in cancer cachexia and its
modification by a high fat diet in mice. Cancer Res 49: 3800–3804
Bibby MC, Double JA, Ali SA, Fearon KCH, Brennan RA, Tisdale MJ (1987)
Characterization of a transplantable adenocarcinoma of the mouse colon
producing cachexia in recipient animals. J Natl Cancer Inst 78: 539–546
Bradshaw RA, Brickley WN, Walker KW (1998) N-terminal processing: the
methionine aminopeptidase and N-alpha-acetyl transferase families.
Trends Biochem Sci 23: 263
Busquets S, Alvarez B, Lopez-Soriano FJ, Argiles JM (2002) Branched-chain
amino acids: a role in skeletal muscle proteolysis in catabolic states?
J Cell Physiol 19: 283–289
Carmichael MJ, Clague MB, Keir MJ, Johston ID (1980) Whole body protein
turnover, synthesis and breakdown in patients with colorectal carcino-
ma. Br J Surg 67: 736–739
Evans WK, Makuch R, Clamon GH, Feld K, Weiner RS, Moran E, Blum R,
Shepherd FA, Jeejeebhoy KW, De Wys WD (1985) Limited impact of
total parenteral nutrition on nutritional status during treatment for small
cell lung cancer. Cancer Res 45: 3347–3353
Gomes-Marcondes MCC, Smith HJ, Cooper JC, Tisdale MJ (2002)
Development of an in-vitro model system to investigate the mechanism
of muscle protein catabolism induced by proteolysis-inducing factor. Br J
Cancer 86: 1628–1633
Hamel FG, Upward JL, Siford GL, Duckworth WC (2003) Inhibition
of proteasome activity by selected amino acids. Metabolism 52:
810–814
Lecker SH, Solomon V, Mitch WE, Goldberg AL (1999) Muscle protein
breakdown and the critical role of the ubiquitin–proteasome pathway in
normal and disease states. J Nutr 129: 227S–237S
Llovera M, Carbo N, Lopez-Soriano J, Garcia-Martinez C, Busquets S,
Alvarez B, Agell N, Costelli P, Lopez-Soriano FJ, Celada A, Argiles JM
(1998) Different cytokines modulate ubiquitin gene expression in rat
skeletal muscle. Cancer Lett 133: 83–87
Lundholm K, Bylund AC, Holm J, Schersten T (1976) Skeletal muscle
metabolism in patients with malignant tumour. Eur J Cancer 12:
465–473
Lundholm K, Bennegard K, Eden E, Rennie MJ (1982) Efflux of
3-methylhistidine from the leg of cancer patients who experience weight
loss. Cancer Res 42: 4809–4818
Malaisse WJ (1984) Branched-chain amino and keto acids as regulators of
insulin and glucagon release. In Branched Chain Amino and Keto Acids
in Health and Disease, Adibi SA, Fekl W, Langenbeck U, Schauder P
(eds) pp 119–133, Switzerland: Karger, Basel
Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, Riccobon A,
Derni S, Pallotti G, Amadori D (1997) Serum levels of tumour necrosis
factor alpha and other cytokines do not correlate with weight loss and
anorexia in cancer patients. Support Care Cancer 5: 130–135
Protein synthesis and degradation in muscle
HJ Smith et al
411
British Journal of Cancer (2004) 91(2), 408–412 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sMcMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS
(1998) Longitudinal study of body cell mass depletion and the
inflammatory response in cancer patients. Nutr Cancer 31: 101–105
Reeds PJ, Fjeld CR, Jahoor F (1997) Do the differences between the amino
acid compositions of acute phase and muscle proteins have a bearing on
nitrogen loss in traumatic states? J Nutr 124: 906–910
Robertson FM, Offner PJ, Ciceri DP, Becker WK, Pruitt BA (1994)
Detrimental hemodynamic effect of nitric oxide synthase inhibition in
septic shock. Arch Surg 129: 149–155
Smith HJ, Lorite MJ, Tisdale MJ (1999) Effect of a cancer cachectic factor on
protein synthesis/degradation in murine C2C12 myoblasts: modulation by
eicosapentaenoic acid. Cancer Res 59: 5507–5513
Tesseraud S, Bigot K, Toovis M (2003) Amino acid availability regulates
S6K1 and protein synthesis in avian insulin-insensitive QMT myoblasts.
FEBS Lett 540: 176–181
Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M (1996)
Characterization of a cancer cachectic factor. Nature 379: 739–742
Vissers YLJ, von Meyenfeldt MF, Deutz MEP (2002) Arginine production in
intestine, liver, muscle and kidney is reduced in tumour-bearing mice
undergoing surgery. Eur J Gastroenterol Hepatol 14: A59–A64
Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001) Mechanism of
attenuation of skeletal muscle protein catabolism in cancer cachexia by
eicosapentaenoic acid. Cancer Res 61: 3604–3609
Whitehouse AS, Tisdale MJ (2003) Increased expression of the ubiquitin–
proteasome pathway in murine myotubes by proteolysis-inducing factor
(PIF) is associated with activation of the transcription factor NF-kB. Br J
Cancer 89: 1116–1122
Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH (2000) Effect of
oral eicosapentaenoic acid on weight loss in patients with pancreatic
cancer. Nutr Cancer 36: 177–184
Williams A, Sun X, Fischer JE, Hasselgren P-O (1999) The expression of
genes in the ubiquitin–proteasome proteolytic pathway is increased in
skeletal muscle from patients with cancer. Surgery 126: 744–750
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J,
Embelton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J
(1998) United Kingdom Co-ordinating Committee on Cancer Research
(UKCCR). Guidelines for the welfare of animals in experimental
neoplasia (second edition). Br J Cancer 77: 1–10
Yoshizawa F (2004) Regulation of protein synthesis by branched-chain
amino acids in vivo. Biochem Biophys Res Commun 313: 417–422
Protein synthesis and degradation in muscle
HJ Smith et al
412
British Journal of Cancer (2004) 91(2), 408–412 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s